Bosentan is a medication used to treat pulmonary arterial hypertension (PAH) and is available in tablet form [3]. It is important to note that Bosentan should only be discontinued under the guidance of a healthcare professional [2].

According to Drug Patent Watch [1], Bosentan is an oral medication that works by blocking the effects of endothelin, a substance in the body that can narrow blood vessels. It is important to note that Bosentan is not a cure for PAH, but rather a treatment to manage the symptoms.

The National Center for Biotechnology Information [2] suggests that discontinuing Bosentan should be done gradually, under the guidance of a healthcare professional. Abrupt discontinuation of Bosentan can lead to worsening of PAH symptoms, including shortness of breath, dizziness, and fatigue. Patients who experience these symptoms after discontinuing Bosentan should seek medical attention immediately.

MedlinePlus [3] also advises patients to not stop taking Bosentan without consulting their healthcare provider. They suggest that healthcare providers may gradually reduce the dose of Bosentan over several days to weeks to avoid withdrawal symptoms.

In conclusion, discontinuing Bosentan should only be done under the guidance of a healthcare professional, and should be done gradually to avoid worsening of PAH symptoms. Patients who experience any symptoms after discontinuing Bosentan should seek medical attention immediately.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/BOSENTAN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2350123/
[3] https://medlineplus.gov/druginfo/meds/a605001.html